Immunologic therapy of multiple sclerosis

Annual Review of Medicine

Volumn 50, Issue , 1999, Pages 291-302

  Arnason, Barry G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Copaxone ; Immunotherapy; Interferon ; Intravenous immunoglobulin

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GADOLINIUM; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MYELIN; SALAZOSULFAPYRIDINE;

ANXIETY; CHILL; DISABILITY; DISEASE ACTIVITY; DISEASE CONTROL; DRUG EFFICACY; DYSPNEA; FEVER; FLU LIKE SYNDROME; FLUSHING; HEART PALPITATION; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MUSCLE FATIGUE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SWEATING; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; CONTRAST MEDIA; DISEASE PROGRESSION; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PEPTIDES; POLYMERS; RECOMBINANT PROTEINS; RECURRENCE;

EID: 0033017354     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.50.1.291     Document Type: Review

References (28)

1. 1. IFNβ Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-61
2. 2. IFNβ Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. 1995. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 44:1277-85
3. 3. Paty DW, Li DK, University of British Columbia MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-67
4. 4. Stone LA, Frank JA, Albert PS, et al. 1995. The effect of interferon-b on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37:611-19
5. 5. Pliskin NH, Hamer DP, Goldstein DS, et al. 1996. Improved neuropsychological function in multiple sclerosis patients receiving Interferon Beta-1b. Neurology 47:1463-68
6. 6. Quality Standards Subcommittee of the American Academy of Neurology. 1994. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 44:1537-40
7. 7. Arnason BGW. 1996. Interferon beta in multiple sclerosis. Clin. Immun. Immunopathol. 81:1-11
8. 8. Jacobs LD, Cookfair DL, Rudick RA, et al. 1996. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 3 9:285-94
9. 9. The PRISMS (Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised, double-blind, placebo-controlled study of Interferon-beta 1a in relapsing-remitting multiple sclerosis: clinical results. Lancet. In press
10. 10. Li DKB, Paty D, UBC MS/MRI Analysis Research Group and The PRISMS (Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis: MRI results. Lancet. In press
11. 11. Bornstein MB, Miller A, Slagle S, et al. 1987. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317:408-14
12. 12. Johnson KP, Brooks BR, Cohen JA, et al. 1995. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-76
13. 13. Johnson KP, Brooks BR, Cohen JA, et al. 1998. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701-8
14. 14. Mancardi GL, Sardanelli F, Parodi RC, et al. 1998. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50:1127-33
15. 15. Bornstein MB, Miller A, Slagle S, et al. 1991. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533-39
16. 16. Arnon R. 1996. The development of Cop 1 (Copaxone7), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immun. Lett. 50:1-15
17. 17. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. 1997. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349:589-93
18. 18. Achiron A, Gabbay U, Gilad R, et al. 1998. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 50:398-402
19. 19. Arnason BG, Dianzani F. 1997. International Workshop on Interferon Antibodies: Executive Summary. South Plainfield, NJ: Catalyst Communications
20. 20. Yudkin PL, Ellison GW, Ghezzi A, et al. 1991. Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051-55
21. 21. Goodkin DE, Rudick R, Vanderbrug-Medendorp S, et al. 1995. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 37:30-40
22. 22. Hauser SL, Dawson DM, Lehrich JR, et al. 1983. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Eng. J. Med. 308:180-83
23. 23. The Canadian Cooperative Multiple Sclerosis Study Group. 1991. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441-46
24. 24. The Multiple Sclerosis Study Group. 1990. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomised double-blinded, placebo-controlled clinical trial. Ann. Neurol. 27:591-605
25. 25. Beutler E, Sipe JC, Romine JS, Koziol JA. 1996. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. USA 93:1716-20
26. 26. Noseworthy JH, O'Brien PC, The Mayo Clinic-Canadian Cooperative MS Study Group. 1997. The Mayo Clinic-Canadian Cooperative study of sulfasalazine (Salazopyrin EN) in active multiple sclerosis: preliminary report. Neurology 48:A340 (Abstr.)
27. 27. Andersen O, Lycke J, Tollesson PO, et al. 1996. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47:890-900
28. 28. Karussis DM, Meiner Z, Lehmann D, et al. 1996. Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide: a double blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47:341-46